Photodynamic Therapy and Cardiovascular Diseases
Aleksander Oskroba1, Dorota Bartusik-Aebisher2, Angelika Myśliwiec3
1Science Club, Faculty of Medicine, Medical University of Lublin, 20-059 Lublin, Poland.
International Journal of Molecular Sciences
|March 13, 2024
Summary
Photodynamic therapy (PDT) shows potential for treating cardiovascular diseases like atherosclerosis, though its clinical use in cardiology is currently limited. This review explores PDT
Area of Science:
- Cardiology
- Biomedical Engineering
- Photomedicine
Background:
- Cardiovascular diseases (CVDs) are a leading global cause of mortality, with heart attacks and stroke being most prevalent.
- Atherosclerosis significantly impacts the development and management of cardiovascular diseases.
- Photodynamic therapy (PDT) is an established treatment for various conditions but is underutilized in cardiology.
Purpose of the Study:
- To review the current effectiveness of photodynamic therapy (PDT) in treating cardiovascular diseases.
- To summarize photosensitizers commonly employed in cardiological applications of PDT.
Main Methods:
- Literature review of existing studies on photodynamic therapy in cardiovascular disease treatment.
- Analysis of experimental and clinical data regarding PDT efficacy and photosensitizer usage in cardiology.
- Synthesis of findings to characterize the therapeutic potential and current limitations of PDT.
Main Results:
- Photodynamic therapy (PDT) demonstrates promise in preclinical and in vitro models for cardiovascular applications.
- Clinical application of PDT in cardiology remains rare, with most evidence derived from experimental settings.
- Specific photosensitizers are identified for their potential use in PDT for cardiovascular conditions.
Conclusions:
- Photodynamic therapy (PDT) presents a potential therapeutic avenue for cardiovascular diseases, particularly atherosclerosis.
- Further clinical research and development are necessary to establish PDT as a standard treatment in cardiology.
- Understanding photosensitizer properties is crucial for optimizing PDT in cardiovascular medicine.
Related Concept Videos
Cardiovascular Drugs: Classification based on Therapeutic Indications
2.8K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.8K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
164
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
164
Electron Transport Chain: Complex I and II
13.2K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
13.2K


